[New clinical tests in diagnosis of hematologic diseases].
Nakahara
K
K
D000933:Antifibrinolytic Agents / Q000032:analysis; D000990:Antithrombin III / Q000032:analysis; D004921:Erythropoietin / Q000032:analysis; D005338:Fibrin Fibrinogen Degradation Products / Q000032:analysis; D005341:Fibrinolysin / Q000032:analysis; D005344:Fibrinopeptide A / Q000032:analysis; D005345:Fibrinopeptide B / Q000032:analysis; D006402:Hematologic Diseases / Q000175:diagnosis*; D006801:Humans; D007074:Immunoglobulin G / Q000032:analysis; D010446:Peptide Fragments / Q000032:analysis; D010447:Peptide Hydrolases / Q000032:analysis; D011486:Protein C / Q000032:analysis; D000979:alpha-2-Antiplasmin
D000933:Antifibrinolytic Agents; D005338:Fibrin Fibrinogen Degradation Products; D007074:Immunoglobulin G; D010446:Peptide Fragments; D011486:Protein C; D000979:alpha-2-Antiplasmin; C046193:antithrombin III-protease complex; C036309:fibrin fragment D; C011468:fibrinmonomer; C033786:fibrinogen Bbeta (15-42); C037742:plasmin-plasmin inhibitor complex; D004921:Erythropoietin; D005344:Fibrinopeptide A; D005345:Fibrinopeptide B; D000990:Antithrombin III; D010447:Peptide Hydrolases; D005341:Fibrinolysin